Day: September 30, 2024

– Study exceeded target enrollment, with an expected topline data readout from the interim analysis expected in 2025 – BridgeBio believes there is an opportunity to pursue Accelerated Approval in the U.S. for BBP-418 in LGMD2I/R9 based on a potential biomarker surrogate endpoint of glycosylated alpha-dystroglycan (αDG) at time of the interim analysis – If successful, BBP-418 could be the first approved therapy for individuals living with LGMD2I/R9 in the U.S. – Enrollment completion announced on 10th annual LGMD Awareness Day, a collaborative yearly effort on September 30th to globally raise awareness of individuals living with LGMD PALO ALTO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused...

LOUISVILLE, Ky., Sept. 30, 2024 (GLOBE NEWSWIRE) — BrightSpring Health Services (“BrightSpring” or “the Company”) (NASDAQ: BTSG), a leading provider of home- and community-based health services for complex populations, today announced that Dr. Steve Miller was appointed as a Class II member of the Board of Directors. Dr. Miller will also serve as a member of the Board’s Audit Committee and as the chair of the Board’s Quality & Compliance and Governance Committee. As a nationally recognized advocate for greater access, affordability, and excellence in healthcare, Dr. Miller brings decades of experience to the Company as a medical researcher, clinician, and administrator across numerous healthcare settings and arenas. Dr. Miller served as the Chief Clinical Officer for Cigna from 2018 to 2022, transitioning to an expert advisor...

Second Annual Collaboration Coincides With Breast Cancer Awareness Month NORWOOD, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) — Betty’s Eddies announced its second annual collaboration with the Keep A Breast Foundation (“KAB”) to continue advancing breast cancer awareness education and supporting the millions of people affected by the disease. The initiative includes redesigned product packaging and a campaign to foster KAB’s mission of reducing breast cancer risk through education, with a focus on early detection. Betty’s Eddie’s all-natural, cannabis fruit chews, handcrafted to suit a variety of specific effects, is one of the award-winning brands produced and distributed by leading multi-state cannabis operator, MariMed Inc. (“MariMed”) (CSE: MRMD) (OTCQX: MRMD). To commemorate the campaign and raise visibility for KAB’s mission,...

ZenaTech Inc.ZenaDrone 1000 drone flying to recharging padTORONTO, Ontario, Sept. 30, 2024 (GLOBE NEWSWIRE) — ZenaTech, Inc. (Nasdaq: ZENA) (“ZenaTech”), a technology company specializing in AI (Artificial Intelligence) drone solutions and enterprise SaaS (Software-as-a-Service) solutions, today announced that its common shares are approved for listing on the Nasdaq Capital Market (“Nasdaq”) under the ticker symbol “ZENA”. ZenaTech’s common shares are expected to commence trading on October 1st, 2024. “Listing on Nasdaq represents a significant achievement for ZenaTech and will help advance the development of our drone solutions, incorporating software and hardware innovation, for inspection, monitoring, compliance, field service, and other applications where we have customer interest,”...

WYOMISSING, Pa., Sept. 30, 2024 (GLOBE NEWSWIRE) — Gaming and Leisure Properties, Inc. (“GLPI” or the “Company”) (NASDAQ: GLPI) today announced the promotion of Chief Operating Officer, Brandon Moore, to the additional role of President, effective immediately. Mr. Moore will continue to report to the Company’s Chairman and Chief Executive Officer, Peter Carlino. “Brandon has played an instrumental role in all of GLPI’s growth and success since we established North America’s first gaming-focused real estate investment trust over ten years ago,” said Peter Carlino. “With his strong legal background, experience in the gaming industry spanning fourteen years, his involvement in the tax-free spin which created GLPI, and over ten years of success as a leader in the REIT industry, I am delighted to have Brandon take on the role of President...

IMPACT trial is evaluating the safety and efficacy of pemvidutide in approximately 190 subjects with MASH; top-line efficacy data expected in Q2 2025 End-of-Phase 2 Meeting for the obesity program with U.S. Food and Drug Administration (FDA) has been scheduled for early November 2024 Company plans to submit Investigational New Drug (IND) applications for pemvidutide in up to three additional indications beginning in Q4 2024 GAITHERSBURG, Md., Sept. 30, 2024 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced completion of patient enrollment in IMPACT, its Phase 2b biopsy-driven trial evaluating pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) and provided an update on additional development and regulatory initiatives related to pemvidutide. “We continue...

MELBOURNE, Australia and PRINCETON, N.J., Sept. 30, 2024 (GLOBE NEWSWIRE) — Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that management will participate in a fireside chat and be available for one-on-one investor meetings at the UBS Virtual Ophthalmology Day 2024 being held on October 2, 2024. UBS Virtual Ophthalmology Day 2024   Fireside chat:  Wednesday, October 2, 2024, 4:00 PM ETPresenter: Frederic Guerard, PharmD, CEOWebcast link: https://kvgo.com/ubs/opthea-ltd-oct-2024 The webcast can also be accessed under “Events & Presentations” in the Investor Relations section of the Company’s website,...

Ratutrelvir was well-tolerated for 10 days and achieved consistent plasma levels in the predicted therapeutic window, without the need for co-administration of ritonavir Phase 2a study expected to begin in H1 2025 in patients with COVID Improving COVID care is an ongoing need, with approximately 50,000 US deaths in 2023 NEWTOWN, Pa., Sept. 30, 2024 (GLOBE NEWSWIRE) — Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing potential oral small molecule therapies for the treatment of respiratory viral diseases, today announced positive topline Phase 1 results for its potential best-in-class COVID (SARS-CoV-2) candidate, ratutrelvir, an oral inhibitor of the Main protease (Mpro). “Topline data indicate that administration of ratutrelvir, our product candidate...

Company to leverage capital and Valor’s expertise for strategic initiatives building market awareness, R&D roadmap, data analysis capabilities, and expanding access to Deep TMS™ Purchase price of US$9.51 represents a 20% premium over 30-day VWAP of BrainsWay’s American Depositary Shares Valor provides growth equity to technology-enabled companies and currently has $18.9B in assets under management BURLINGTON, Mass. and JERUSALEM, Sept. 30, 2024 (GLOBE NEWSWIRE) — BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it has entered into a securities purchase agreement with an affiliate of Valor Equity Partners (“Valor”) for a private investment financing (the “PIPE”) expected...